Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b_20260413-221849",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Peripheral Anergy Induction Maintains Tolerance in AQP4-Specific B Cells\",\n      \"mechanism\": \"AQP4-specific B cells that escape central tolerance become functionally anergic upon encountering antigen in secondary lymphoid organs, maintaining unresponsiveness through reduced BCR signaling and altered metabolic states.\",\n      \"target_gene\": \"BTK\",\n      \"confidence_score\": 0.75,\n      \"novelty_score\": 0.5,\n      \"feasibility_score\": 0.8,\n      \"impact_score\": 0.8,\n      \"composite_score\": 0.73,\n      \"testable_prediction\": \"Measure calcium signaling responses and BCR proximal kinase phosphorylation in AQP4-tetramer+ B cells from healthy controls versus NMO patients; anergic cells will show blunted signaling.\",\n      \"skeptic_concern\": \"Anergic cells are reversible and may reactivate if cytokine milieu shifts, raising questions about durability of tolerance maintenance.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Regulatory B Cell (B10) Mediated Suppression of AQP4-Reactive Clones\",\n      \"mechanism\": \"IL-10-producing regulatory B cells actively suppress AQP4-specific B cell activation through cytokine-mediated inhibition in germinal centers, preventing autoantibody class-switching.\",\n      \"target_gene\": \"IL10\",\n      \"confidence_score\": 0.65,\n      \"novelty_score\": 0.6,\n      \"feasibility_score\": 0.75,\n      \"impact_score\": 0.7,\n      \"composite_score\": 0.67,\n      \"testable_prediction\": \"Deplete B10 cells in a humanized mouse model using CD19-directed antibodies and measure anti-AQP4 antibody titers; tolerance should break upon depletion.\",\n      \"skeptic_concern\": \"Breg-mediated suppression is non-antigen-specific and may not explain durable tolerance maintenance to a single autoantigen.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Central Tolerance via CNS Antigen Presentation in Bone Marrow Niches\",\n      \"mechanism\": \"Microglial precursor cells or ectopic CNS-resident progenitor cells in bone marrow present AQP4 to developing B cells, enabling RAG-mediated receptor editing of autoreactive BCRs.\",\n      \"target_gene\": \"RAG1/2\",\n      \"confidence_score\": 0.5,\n      \"novelty_score\": 0.85,\n      \"feasibility_score\": 0.35,\n      \"impact_score\": 0.75,\n      \"composite_score\": 0.60,\n      \"testable_prediction\": \"Perform single-cell RNA sequencing of bone marrow stromal cells to identify AQP4-expressing populations; validate with AQP4-immunostaining of bone marrow sections.\",\n      \"skeptic_concern\": \"AQP4 expression in bone marrow is not established; the anatomical paradox of CNS antigens accessing bone marrow for central tolerance remains unresolved.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"B cells are actively involved in maintaining tolerance to AQP4, not passively ignoring the autoantigen\",\n    \"Peripheral tolerance mechanisms are plausible and testable using contemporary B cell assays\",\n    \"Failure of B cell tolerance mechanisms likely underlies NMO pathogenesis\"\n  ],\n  \"dissent_points\": [\n    \"Mechanistic site of tolerance (central vs. peripheral) remains contested; the anatomical paradox raised by the skeptic challenges central tolerance hypotheses without resolution\"\n  ],\n  \"debate_summary\": \"The theorist proposed central tolerance via bone marrow receptor editing, but the skeptic's anatomical paradox critique—AQP4 is CNS-restricted with no established bone marrow presence—substantially undermines this hypothesis. The expert correctly noted domain-specific context. The ranked synthesis prioritizes peripheral anergy (highest composite score, addresses anatomical paradox, strong feasibility) over Breg-mediated suppression and speculative central tolerance with novel-but-low-feasibility bone marrow antigen presentation.\"\n}\n```",
  "tokens_used": "945"
}